Assenagon Asset Management S.A. Acquires 155,011 Shares of Insmed, Inc. $INSM

Key Points

• Assenagon Asset Management increased its Insmed stake by 245%, purchasing 155,011 additional shares to own 218,270 shares valued at approximately $23.3 million.
• Insmed reported strong quarterly results, with revenue rising 296.1% year over year to $425.5 million and a loss of $0.06 per share—well ahead of analyst expectations. BRINSUPRI sales significantly exceeded forecasts, prompting the company to raise its 2026 revenue guidance.
• Analysts remain broadly bullish, with a consensus “Buy” rating and an average price target of $205.26, although Insmed continues to report negative net income and return on equity.

Assenagon Asset Management S.A. increased its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 245.0% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 218,270 shares of the biopharmaceutical company's stock after purchasing an additional 155,011 shares during the period. Assenagon Asset Management S.A. owned approximately 0.10% of Insmed worth $23,272,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC lifted its stake in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 53 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Insmed by 10.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company's stock valued at $130,000 after purchasing an additional 69 shares during the period. Private Advisor Group LLC boosted its stake in shares of Insmed by 1.8% during the first quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company's stock valued at $777,000 after purchasing an additional 82 shares during the period. Glenmede Trust Co. NA grew its holdings in shares of Insmed by 5.4% in the first quarter. Glenmede Trust Co. NA now owns 1,916 shares of the biopharmaceutical company's stock worth $313,000 after purchasing an additional 98 shares during the last quarter. Finally, Allworth Financial LP grew its holdings in shares of Insmed by 20.5% in the fourth quarter. Allworth Financial LP now owns 635 shares of the biopharmaceutical company's stock worth $111,000 after purchasing an additional 108 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Evercore reiterated an "outperform" rating and set a $170.00 price target on shares of Insmed in a report on Friday. Roth Capital reissued a "buy" rating on shares of Insmed in a research note on Monday, June 8th. Wells Fargo & Company boosted their target price on Insmed from $161.00 to $169.00 and gave the company an "overweight" rating in a research note on Friday. Royal Bank Of Canada decreased their target price on Insmed from $205.00 to $195.00 and set an "outperform" rating for the company in a report on Friday, June 5th. Finally, UBS Group reaffirmed a "buy" rating and issued a $172.00 price target on shares of Insmed in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Insmed currently has an average rating of "Buy" and a consensus target price of $205.26.

Insmed Stock Performance

Insmed stock opened at $131.10 on Monday. The business's fifty day moving average is $105.14 and its 200 day moving average is $129.01. Insmed, Inc. has a one year low of $90.39 and a one year high of $212.75. The stock has a market capitalization of $28.42 billion, a PE ratio of -31.90 and a beta of 0.81. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm had revenue of $425.49 million during the quarter, compared to analysts' expectations of $395.50 million. During the same period in the previous year, the company earned ($1.70) earnings per share. The firm's quarterly revenue was up 296.1% on a year-over-year basis. On average, sell-side analysts predict that Insmed, Inc. will post -2.37 EPS for the current year.

Key Stories Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: BRINSUPRI sales significantly exceeded expectations. Second-quarter revenue reached $309.2 million, up 49% from the first quarter, reflecting strong commercial uptake of the company’s bronchiectasis treatment. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion-$1.40 billion and increased its peak-sales estimate to more than $7 billion. Insmed Second-Quarter 2026 Results
• Positive Sentiment: Insmed beat quarterly estimates. Total revenue was $425.5 million, up 296.1% year over year and above the approximately $393.7 million consensus forecast. The company reported a loss of $0.06 per share, substantially narrower than the expected $0.67 loss and the $1.70 loss recorded a year earlier. Insmed Tops Q2 Earnings Estimates
• Positive Sentiment: Long-term growth expectations improved. Insmed lifted its combined peak-revenue outlook for BRINSUPRI, TPIP and ARIKAYCE to more than $14 billion, including over $6 billion for TPIP. It maintained 2026 ARIKAYCE revenue guidance of $450 million-$470 million and provided total 2026 revenue guidance of approximately $1.7 billion-$1.9 billion.
• Positive Sentiment: Trading activity signaled strong investor interest. Call-option volume rose roughly 469% above average, while reports described the stock as gaining about 30%-34% following the earnings release. Analysts also maintained an overall “Buy” recommendation.
• Neutral Sentiment: Profitability remains limited. Despite the improved loss, Insmed continues to report negative net income and return on equity as it invests in developing and commercializing its pipeline.

Insider Transactions at Insmed

In other news, COO Roger Adsett sold 2,370 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $242,379.90. Following the transaction, the chief operating officer directly owned 98,603 shares of the company's stock, valued at $10,084,128.81. This represents a 2.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Sara Bonstein sold 2,404 shares of Insmed stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the sale, the chief financial officer directly owned 69,082 shares of the company's stock, valued at $7,065,016.14. The trade was a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 54,590 shares of company stock valued at $5,793,738 over the last 90 days. 2.10% of the stock is owned by corporate insiders.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source